TABLE 2.
DiaSorin antibody levels on additional subjects who received either the Pfizer (P) or Moderna (M) vaccine
| Case age‐sex‐vaccine | Pre (days before vaccine) | First vaccine days from diagnosis | Post (days after vaccine(s) | Fold change | PRNT |
|---|---|---|---|---|---|
| Case4 61‐F‐P | 31.9 (23) | 185 | 1235 (22) | 39 | 6171 |
| Case 5 56‐F‐P | <3.8 (55) | 113 | 245 (36/14) | 66 | 887 |
| Case 6 41‐F‐M | 39.4 (254) | 276 | 6132 (25) | 156 | 30,848 |
| Case 7 46‐F‐P | 39.1 (118) | 281 | 6027 (20) | 154 | 34,221 |
| Case 8 39‐F‐P | 39.2 (247) | 273 | 4851 (20) | 124 | >43,740 |
| Case 9 27‐F‐P | 379 (20) | 250 | 3810 (16) | 10 | 41,045 |
| Case 10 40‐F‐M | 84 (123) | 292 | 7854 (17) | 93 | >43,740 |
| Case 11 61‐F‐P | 37.6 (146) | 195 | 3333 (21) | 89 | 37,538 |